DDrare: Database of Drug Development for Rare Diseases

Topical infliximab (DrugBank: Infliximab)

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
38	スティーヴンス・ジョンソン症候群	1
39	中毒性表皮壊死症	1
162	類天疱瘡（後天性表皮水疱症を含む。）	1

38. スティーヴンス・ジョンソン症候群　［臨床試験数：11，薬物数：19（DrugBank：8），標的遺伝子数：14，標的パスウェイ数：98］

Searched query = "Stevens-Johnson syndrome", "SJS", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 11 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)	Withdrawn	18 Years	80 Years	All	0	Phase 1;Phase 2	United States;Canada

39. 中毒性表皮壊死症　［臨床試験数：11，薬物数：18（DrugBank：8），標的遺伝子数：11，標的パスウェイ数：101］

Searched query = "Toxic epidermal necrolysis", "Toxic epidermal necrosis", "TEN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 11 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)	Withdrawn	18 Years	80 Years	All	0	Phase 1;Phase 2	United States;Canada

162. 類天疱瘡（後天性表皮水疱症を含む。）　［臨床試験数：70，薬物数：117（DrugBank：46），標的遺伝子数：30，標的パスウェイ数：128］

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 70 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)	Withdrawn	18 Years	80 Years	All	0	Phase 1;Phase 2	United States;Canada